Home Cart Sign in  
Chemical Structure| 61276-17-3 Chemical Structure| 61276-17-3

Structure of Acteoside
CAS No.: 61276-17-3

Chemical Structure| 61276-17-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Acteoside, is a natural product isolated and purified from the herbs of Cistanche deserticola Y.C. Ma with known antioxidant activity. It is a protein kinase C inhibitor (IC50 =25 μM).

Synonyms: Kusaginin; TJC160; Acetoside

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Acteoside

CAS No. :61276-17-3
Formula : C29H36O15
M.W : 624.59
SMILES Code : O=C(O[C@@H]1[C@@H](CO)O[C@@H](OCCC2=CC=C(O)C(O)=C2)[C@H](O)[C@H]1O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)/C=C/C4=CC=C(O)C(O)=C4
Synonyms :
Kusaginin; TJC160; Acetoside
MDL No. :MFCD00221751

Safety of Acteoside

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Acteoside

epigenetics
GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
C5N cells 500 μM 24 h Acteoside showed lower toxicity in C5N cells but increased cellular ROS levels. Redox Biol. 2018 Jun;16:169-178
A5 cells 500 μM 24 h Acteoside showed increased toxicity in A5 cells, elevated cellular ROS levels, and suppressed MMP-2 and MMP-9 enzymatic activities. Redox Biol. 2018 Jun;16:169-178
RAW 264.7 cell line 50 µM 24 h Evaluate the inhibitory effect of Acteoside on macrophage activation, showing significant inhibition of IL-6 secretion at 50 μmol/L. Engineering (Beijing). 2023 Jan;20:63-76.
Hepatocytes (BRL-3A) 25, 50, 100 μM 16 h To investigate the effect of Acteoside on HR-induced hepatocyte injury. Results showed that Acteoside reduced the release of injury markers (e.g., HMGB1) from hepatocytes under HR conditions. Int J Biol Sci. 2023 Sep 18;19(15):4967-4988
Liver sinusoidal endothelial cells (LSECs) 25, 50, 100 μM 12 h To evaluate the effect of Acteoside on hypoxia-reoxygenation (HR)-induced senescent phenotype in LSECs. Results showed that Acteoside significantly inhibited the upregulation of senescence markers (e.g., p21, p53) and restored the expression of cell cycle checkpoints (e.g., cdk2, ccnd1). Int J Biol Sci. 2023 Sep 18;19(15):4967-4988

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Hepatic ischemia-reperfusion injury (HIRI) model Oral gavage 25, 50, 100 mg/kg Once daily for 7 days To evaluate the protective effect of Acteoside on liver injury in HIRI mice. Results showed that Acteoside significantly ameliorated HIRI-induced liver histopathological injury, abnormal liver function indicators, and senescent phenotype of LSECs. Int J Biol Sci. 2023 Sep 18;19(15):4967-4988

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03641248 Osteoarthritis, Knee Early Phase 1 Not yet recruiting June 2019 United States, Missouri ... More >> Univ of Missouri Health Care Center Not yet recruiting Columbia, Missouri, United States, 65211 Contact: Dean Hainsworth, MD    573-882-4894    ClinicalResearch@health.missouri.edu Less <<
NCT02662283 IGA Nephropathy Phase 2 Phase 3 Unknown November 2016 China, Guangdong ... More >> Department of Nephrology, 6th Affiliated Hospital, Sun Yat-Sen University Guangzhou, Guangdong, China, 510655 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.60mL

0.32mL

0.16mL

8.01mL

1.60mL

0.80mL

16.01mL

3.20mL

1.60mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories